Lulama R. Molife
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Journal: European urology
Published: December 09, 2023
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.
Journal: Japanese journal of clinical oncology
Published: November 08, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Journal: European urology
Published: January 17, 2023
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
Journal: Future oncology (London, England)
Published: April 14, 2021
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 08, 2020
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
Journal: British journal of clinical pharmacology
Published: November 04, 2019
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Journal: British journal of cancer
Published: October 28, 2019
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 28, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Journal: Clinical pharmacokinetics
Published: March 17, 2019
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Journal: Advances in therapy
Published: August 13, 2018
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Journal: British journal of cancer
Published: May 31, 2018
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.
Journal: Journal of neuro-oncology
Published: October 09, 2017
Last Updated: 09/26/2026